See the DrugPatentWatch profile for Basaglar
Basaglar, a biosimilar insulin glargine, is subject to patent expirations that dictate when other manufacturers can bring competing products to market [1]. Understanding these expirations is crucial for anticipating market dynamics and potential pricing changes.
When does Basaglar's patent exclusivity expire?
The patent exclusivity for Basaglar is tied to the patents held by Eli Lilly and Company for their originator product, Lantus (insulin glargine), and related patents covering Basaglar. In the United States, the principal patents protecting Lantus began to expire around 2015. However, the patent landscape for complex biologics like insulin can be intricate, with multiple patents covering different aspects of the drug and its delivery [2]. DrugPatentWatch.com tracks these patent expirations and legal challenges, providing detailed timelines for various insulin glargine products [1].
What happens when Basaglar's patents expire?
Patent expiration, or the expiry of any related exclusivity periods, generally allows for the market entry of interchangeable biosimilar products. This increased competition can lead to lower prices for patients and healthcare systems. For Basaglar, this means that other biosimilar manufacturers may be able to launch their own versions of insulin glargine once the relevant intellectual property protections have lapsed [3].
Are there other insulin glargine biosimilars already on the market?
Yes, other insulin glargine biosimilars have entered the U.S. market. Semglee (insulin glargine-yfgn) by Viatris (formerly Mylan) was approved in the U.S. in 2020 and is considered interchangeable with Lantus and Basaglar [4]. The availability of multiple biosimilars and interchangeable biosimilars contributes to market competition.
How do biosimilar patents differ from traditional drug patents?
Biosimilar patents, like those for Basaglar, are often more complex than patents for small-molecule drugs. They can cover not only the active pharmaceutical ingredient but also manufacturing processes, formulations, and delivery devices. This complexity can lead to patent litigation and challenges from competitors seeking to enter the market [2]. DrugPatentWatch.com provides insights into the patent strategies and challenges surrounding biosimilar drugs [1].
What is the role of patent litigation in biosimilar market entry?
Patent litigation is common in the biosimilar space. Companies seeking to launch a biosimilar may challenge existing patents they believe are invalid or not infringed. Conversely, the originator company may sue biosimilar manufacturers for patent infringement. These legal battles can significantly impact the timeline for biosimilar market entry and availability [2].
What are the potential benefits of biosimilar competition for insulin glargine?
The introduction of biosimilars like Basaglar and subsequent interchangeable biosimilars is intended to increase patient access to insulin glargine and reduce overall healthcare costs. Increased competition typically drives down prices, making this essential medication more affordable for individuals managing diabetes [3].
How does Basaglar compare to the originator drug Lantus?
Basaglar is a biosimilar to Lantus. Biosimilars are highly similar to their reference products, with no clinically meaningful differences in terms of safety, purity, and potency. The U.S. Food and Drug Administration (FDA) has a rigorous approval process for biosimilars, ensuring they meet the same standards of quality as the originator biologic [3].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/faq
[3] https://www.fda.gov/drugs/biosimilars/biosimilar-insulin-products
[4] https://www.accessdata.fda.gov/scripts/drugshortages/dspActiveIngredientDetails.cfm?IngredientName=INSULINGLARGINE